DuPont touts favorable Cardiolite studies

Article

Studies presented at this month’s American Heart Association meeting in Atlanta suggest that heart scans conducted with Cardiolite, a myocardial perfusion agent from North Billerica, MA-based Du Pont, may help clinicians predict a patient’s

Studies presented at this month’s American Heart Association meeting in Atlanta suggest that heart scans conducted with Cardiolite, a myocardial perfusion agent from North Billerica, MA-based Du Pont, may help clinicians predict a patient’s risk of future cardiac events and avoid performing invasive procedures. Researchers at Cedars Sinai Medical Center used Cardiolite in SPECT scans on 2600 patients to evaluate whether assessing cardiac function and perfusion would help predict the likelihood of both fatal and nonfatal heart attacks. The team found that cardiac function—the blood volume passing through the heart—is a strong cardiac death indicator, while perfusion—blood flow to the heart tissue—is a strong nonfatal heart attack risk indicator. The group surmised that evaluating these two factors could increase physicians’ accuracy in assessing a patient’s future heart attack risk.

In another study, conducted at the Medical College of Virginia, researchers used Cardiolite in the emergency room to assess whether patients with chest pain required coronary angiography. The 1000-patient study showed that fewer patients required the procedure when Cardiolite was used to appraise their condition. In a related study at MCV, 600 patients with chest pain but at low risk for heart attack were assessed with a Cardiolite scan, allowing clinicians to evaluate the extent of heart damage without more invasive testing.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.